DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sotorasib
Sotorasib
Analyst WCLC Presentation
Elicio Therapeutics, Inc. Form S-1/A Filed 2021-07-13
Recent Advances in Oligonucleotide Therapeutics in Oncology
Precision Medicine in Colorectal Cancer 2021
(FDA) Approved Bristol Myers Squibb's (Bms.Com) Br
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
5.01.540 Miscellaneous Oncology Drugs
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Sotorasib Data at Esmo Virtual Congress 2020
Full Prescribing Information [FDA]
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Oncology Orals Solid Tumors
Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
Amgen Pipeline Updates
RAS-Targeted Therapies Amanda R
Drugs with Special Ordering Procedures (SAP Chart)
The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Top View
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
KPCO Investigator Trials
Specialty Pipeline: March 2021
Turning the Tide on Cancer April 2021 Forward-Looking Statements
Oncology Medications Policy (1403)
214665Orig1s000
The Role of Pharmacists in Optimizing Molecular Testing with Evolving Biomarkers and Treatment for Non-Small Cell Lung Cancer
Our Clinical Trials
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Optimizing Use of Biomarkers in Managing Metastatic Non−Small Cell Lung Cancer the Role of the Oncology Health Care Team Faculty Information
CHMP Agenda of the 25-29 January 2021 Meeting
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
Mandatory Specialty Drug List
National Institute for Clinical Excellence
Asco 2021 Highlights
2021 Standard Opt out with ACSF
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
ATC/DDD Classification (Temporary)
Orange Book Cumulative Supplement 7 July 2021
WHO Drug Information Contents
2021 Prior Authorization Requirements Special Needs Plans
Esmo 2020 Lung: Immunotherapy in Nsclc and Mesothelioma
Mechanisms of Resistance to KRASG12C Inhibitors
Company Overview August 5, 2021 Safe Harbor
(STA) Sotorasib for Previously Treat
Preliminary Program All Times CDT
2020 FDA Drug Approvals Priority Reviews, for Products That Would the FDA Approved 53 Novel Drugs in 2020, the Second Highest Count in Over 20 Years
The KRAS-G12C Inhibitor: Activity and Resistance
Restricted Use – Prior Approval Drug List
Our Clinical Trials
Pathway-Directed Therapy in Multiple Myeloma
Amgen Inc. (Exact Name of Registrant As Specified in Its Charter) Delaware 95-3540776 (State Or Other Jurisdiction of (I.R.S
FDA Approves LUMAKRAS
MEI AACR 2021 Poster FINAL
Prior Authorization Criteria
Horizon Scanning Status Report, March 2021, Volume 3, Issue 1
18,750,000 Shares Common Stock